Tagomics
Tagomics Ltd., a pioneering biomarker discovery and diagnostics company, has developed a novel multiomics platform, Interlace, which offers a seamless solution for multiomic profiling to unlock disease-associated DNA biomarkers from a range of biological sources. Based in Cambridge, UK, Tagomics was launched in 2021 as a spin out from The University of Birmingham to build upon research led by Dr Robert Neely, the company’s Chief Scientific Officer. The company has since developed a suite of pioneering 'omics' technologies, including its Interlace multiomic platform, which seamlessly combines the Company’s novel approach to epigenomics (studying chemical 'switches' on the genome) with genomics (detecting mutations and other structural variants) and fragmentomics (the analysis of DNA fragmentation patterns in the blood). By integrating these methods and applying advanced data analysis and machine learning, the Tagomics Interlace platform can provide a 360° understanding of human health and disease.Content by Tagomics
| 2 min read
Activace platform enables targeted, genome-wide profiling of unmethylated DNA regions, providing a comprehensive view of the epigenome that can be scaled to the study of large patient cohorts
| 5 min read
Methylation profiling of cell-free DNA is opening new possibilities for detecting cancer at its earliest, pre-symptomatic stages, offering a potential breakthrough in how and when disease is found.
| 2 min read
Early detection test to be developed in collaboration with the Salford Royal NHS Foundation Trust and the Northern Care Alliance Research Collection biobank
Page 1 of 1 - 3 Total Items
